enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Why Ionis Pharmaceuticals Stock is Trading Lower Today - AOL

   www.aol.com/news/why-ionis-pharmaceuticals-stock...

   Ionis Pharmaceuticals Stock Price And Volume Action Ionis Pharmaceuticals (NASDAQ:IONS) is currently down 17.47% to a price of $46.29. Tuesday the stock has been traded at a volume of 2.55 million ...

3. US FDA approves Ionis Pharma's genetic disorder drug - AOL

   www.aol.com/news/us-fda-approves-ionis-pharmas...

   (Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's ...

4. Ionis Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Ionis_Pharmaceuticals

   Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...

5. Why Ionis Pharmaceuticals (IONS) Might Surprise This ... - AOL

   www.aol.com/news/why-ionis-pharmaceuticals-ions...

   For premium support please call: 800-290-4726 more ways to reach us

6. Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss - AOL

   www.aol.com/news/ionis-ions-q1-loss-widens...

   Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

7. Ionis Pharmaceuticals Collects Royalties -- and Spends It All

   www.aol.com/news/ionis-pharmaceuticals-collects...

   For premium support please call: 800-290-4726 more ways to reach us

8. America’s Most Admired Lawbreaker - The Huffington Post

   highline.huffingtonpost.com/miracleindustry/...

   By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.

9. Ionis' (IONS) Partner to Begin New Huntington's Disease Study

   www.aol.com/news/ionis-ions-partner-begin...

   For premium support please call: 800-290-4726 more ways to reach us